Empowered Funds LLC Has $851,000 Position in Henry Schein, Inc. $HSIC

Key Points

• Empowered Funds LLC cut its Henry Schein stake by 59.2% in the first quarter, selling 16,735 shares and retaining 11,551 shares worth approximately $851,000. Institutional investors and hedge funds collectively own 96.62% of the company.
• Analyst sentiment is mixed but generally positive, with eight Buy, six Hold and one Sell rating. The consensus price target is $92.27, with recent targets ranging from $95 to $112.
• Henry Schein exceeded quarterly expectations, reporting $1.27 in EPS versus a $1.24 consensus estimate and $3.46 billion in revenue, up 6.7% year over year. The company reaffirmed fiscal 2026 EPS guidance of $5.29–$5.39.

Empowered Funds LLC lessened its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 59.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,551 shares of the company's stock after selling 16,735 shares during the period. Empowered Funds LLC's holdings in Henry Schein were worth $851,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein during the 2nd quarter valued at approximately $25,000. MUFG Securities EMEA plc bought a new stake in shares of Henry Schein in the 2nd quarter valued at $27,000. Federated Hermes Inc. acquired a new stake in shares of Henry Schein during the fourth quarter worth $32,000. Los Angeles Capital Management LLC acquired a new stake in shares of Henry Schein during the fourth quarter worth $37,000. Finally, EverSource Wealth Advisors LLC raised its stake in Henry Schein by 167.4% during the first quarter. EverSource Wealth Advisors LLC now owns 936 shares of the company's stock worth $69,000 after buying an additional 586 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Robert W. Baird set a $97.00 target price on shares of Henry Schein in a report on Wednesday, May 6th. Citigroup reiterated a "buy" rating and set a $112.00 price target (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. Piper Sandler lifted their price objective on Henry Schein from $91.00 to $95.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. BTIG Research reissued a "buy" rating and issued a $100.00 price objective on shares of Henry Schein in a research note on Wednesday, August 5th. Finally, Barrington Research set a $104.00 target price on Henry Schein in a research report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $92.27.

Henry Schein Trading Down 0.3%

NASDAQ:HSIC opened at $89.52 on Tuesday. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $92.18. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $9.98 billion, a price-to-earnings ratio of 26.10, a PEG ratio of 1.71 and a beta of 0.80. The firm has a fifty day simple moving average of $85.04 and a two-hundred day simple moving average of $79.16.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.03. The firm had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The business's quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Analysts expect that Henry Schein, Inc. will post 5.35 EPS for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source